MedPath

A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 2
Completed
Conditions
Chronic Lymphocytic Leukemia
Registration Number
NCT00073489
Lead Sponsor
Astellas Pharma Inc
Brief Summary

The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.

Detailed Description

The primary objective of this study is to determine the activity of OSI-461 given twice daily orally in previously untreated CLL patients. The secondary objective is to evaluate the safety profile of OSI-461 in this patient population.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
23
Inclusion Criteria
  • Diagnosis of CLL established by bone marrow aspiration and biopsy or flow cytometry of peripheral blood.
  • No previous therapy for CLL.
  • Expected remaining life span greater than or equal to six months.
  • 18 years or older.
  • Willingness and ability to sign an informed consent.
Exclusion Criteria
  • Other active malignancy or history of treatment of any malignancy (excluding non-melanoma skin cancer) within the previous three years.
  • History of other malignancy which could affect the diagnosis or assessment of OSI-461.
  • Previous therapy for CLL.
  • Use of an investigational medication or device within one month of initiating study therapy.
  • Concurrent immunotherapy.
  • Use of steroids at the time of enrollment (patients who require steroids after enrollment may remain on study).
  • Any condition or any medication which may interfere with the conduct of the study.
  • Serious uncontrolled intercurrent medical or psychiatric illness, including serious infection.
  • Evidence of CNS involvement.
  • Pregnant or nursing women.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (15)

Tyler Cancer Center

🇺🇸

Tyler, Texas, United States

Arizona Hematology & Oncology Associates

🇺🇸

Phoenix, Arizona, United States

Oncology/Hematology Associates of Kansas City

🇺🇸

Kansas City, Missouri, United States

Iowa Oncology Associates

🇺🇸

Cedar Rapids, Iowa, United States

Florida Oncology Associates

🇺🇸

Jacksonville, Florida, United States

Dayton Oncology/Hematology Consultants

🇺🇸

Dayton, Ohio, United States

Willamette Valley Cancer Center

🇺🇸

Eugene, Oregon, United States

Hematology Oncology Associates of South Texas

🇺🇸

San Antonio, Texas, United States

Rocky Mountain Cancer Centers

🇺🇸

Aurora, Colorado, United States

Southwest Regional Cancer Center

🇺🇸

Austin, Texas, United States

Cancer Centers of the Carolinas

🇺🇸

Greenville, South Carolina, United States

Cancer Care Northwest

🇺🇸

Spokane, Washington, United States

Oncology & Hematology Associates of Southwest Virginia

🇺🇸

Roanoke, Virginia, United States

Ocala Oncology Center

🇺🇸

Ocala, Florida, United States

Piedmont Hem Onc Assoc, P.A.

🇺🇸

Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath